-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, HVzvVz8Ey9o0DDMlDsWgOoMsE2soHphHJAChOARXn8CzkDE6zalAu9RoSjudqERx jghbefignkCtLj+MCmnTrA== 0001104659-06-081300.txt : 20061213 0001104659-06-081300.hdr.sgml : 20061213 20061213172203 ACCESSION NUMBER: 0001104659-06-081300 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20061213 ITEM INFORMATION: Regulation FD Disclosure FILED AS OF DATE: 20061213 DATE AS OF CHANGE: 20061213 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MEDIMMUNE INC /DE CENTRAL INDEX KEY: 0000873591 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 521555759 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-19131 FILM NUMBER: 061274964 BUSINESS ADDRESS: STREET 1: 35 W WATKINS MILL RD CITY: GAITHERSBURG STATE: MD ZIP: 20878 BUSINESS PHONE: 3014170770 MAIL ADDRESS: STREET 1: 35 W WATKINS MILL ROAD CITY: GAITHERSBURG STATE: MD ZIP: 20878 8-K 1 a06-25713_18k.htm CURRENT REPORT OF MATERIAL EVENTS OR CORPORATE CHANGES

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D. C.  20549

 

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

 

 

Date of Report (Date of earliest event reported)    December 13, 2006

 

 

MedImmune, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware

 

0-19131

 

52-1555759

(State or other jurisdiction of incorporation or organization)

 

(Commission File No.)

 

(I.R.S. Employer Identification No.)

 

One MedImmune Way, Gaithersburg, MD 20878

(Address of principal executive offices) (Zip Code)

 

 

Registrant’s telephone number, including area code (301) 398-0000

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 



 

Item 7.01               Regulation FD Disclosure.

MedImmune, Inc. and its Board of Directors have received correspondence from David A. Katz of Matrix Asset Advisors, Inc. suggesting that MedImmune consider a strategic sale.  The Board has considered this suggestion and continues to unanimously believe that the best way for MedImmune to deliver value to its shareholders is to continue to execute on its business plan.

 



SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

MedImmune, Inc.

 

 

 

 

 

 

Date: December 13, 2006

 

/s/: William C. Bertrand Jr., Esq.

 

 

William C. Bertrand Jr., Esq.

 

 

Senior Vice President and General Counsel

 

 


 -----END PRIVACY-ENHANCED MESSAGE-----